Phase 1 Open-Label Study to Assess Pharmacokinetic and Pharmacodynamic Parameters Following Dosing with an Anti-Tumor Necrosis Factor Monoclonal Antibody (Humira, adalimumab) Enema in Patients with Active Ulcerative Colitis
Latest Information Update: 21 Dec 2022
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biora Therapeutics
- 26 Oct 2022 Results investigating the effects of topical dosing of adalimumab in active ulcerative colitis patients, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 02 Feb 2022 Actual date of last participant enrolled is 28/06/2021 according to Australian New Zealand Clinical Trials Registry record.
- 02 Feb 2022 Status changed from recruiting to discontinued.